II. Indications
III. Contraindications
IV. Mechanism
V. Dosing: Adults
-
Hypertension or Diabetic Nephropathy
- Start 150 mg orally daily
- Start 75 mg orally daily in elderly, concurrent Diuretic use
- Maximum 300 mg/day
VI. Medications: Combinations
- Hydrochlorothiazide and Irbesartan (Avalide)
VII. Adverse Effects
VIII. Safety
- See Angiotensin Receptor Blocker
- Pregnancy Category X
- Unknown Safety in Lactation
IX. Resources
X. References
- (2018) Presc Lett, Resource #340901, Angiotensin Receptor Blocker (ARB) Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
irbesartan (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
IRBESARTAN 150 MG TABLET | Generic | $0.18 each |
IRBESARTAN 300 MG TABLET | Generic | $0.24 each |
IRBESARTAN 75 MG TABLET | Generic | $0.17 each |
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB | Generic | $0.19 each |
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB | Generic | $0.24 each |
avapro (on 1/3/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
AVAPRO 150 MG TABLET | Generic | $0.18 each |
AVAPRO 300 MG TABLET | Generic | $0.24 each |
Ontology: irbesartan (C0288171)
Definition (NCI) | A nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. (NCI05) |
Definition (CSP) | antihypertensive; nonpeptide angiotension 1 subtype; angiotension 2 receptor antagonist. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081309 |
SnomedCT | 108585000, 386877005 |
LNC | LP171611-9 |
English | 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one, 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, irbesartan, irbesartan (medication), IRBESARTAN, irbesartan [Chemical/Ingredient], Irbesartan, Irbesartan (product), Irbesartan (substance) |
Spanish | irbesartano (sustancia), irbesartano, irbesartán (producto), irbesartán (sustancia), irbesartán |
Ontology: Avapro (C0595301)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081309 |
English | irbesartan (Avapro), avapro, aprovel, karvea, Aprovel, Karvea, Sanofi Winthrop Brand of Irbesartan, BMS Brand of Irbesartan, Bristol Myers Brand of Irbesartan, Avapro |